{"prompt": "['Protocol:', 'Sponsor-Investigator Initiated CRI #15-05', 'Title:', 'Bridging Care to HCV Treatment Among Opioid Dependent', 'Patients on Buprenorphine/naloxone Maintenance Therapy: A', 'Pilot Study of Treating HCV with Epclusa at a Psychiatrist-staffed', 'Outpatient Addiction Clinic', 'Protocol:', 'V7.0 September 13, 2017', 'NCT03235154']['CLINICAL STUDY PROTOCOL --- CONFIDENTIAL', 'Protocol:', 'Sponsor-Investigator Initiated CRI #15-05', 'Title:', 'Bridging Care to HCV Treatment Among Opioid Dependent Patients on', 'Buprenorphine/naloxone Maintenance Therapy: A Pilot Study of Treating HCV with', 'Epclusa at a Psychiatrist-staffed Outpatient Addiction Clinic', 'Protocol:', 'V7.0 September 13, 2017', 'Sponsor:', 'Community Research Initiative of New England', '529 Main Street', 'Boston, MA 02129', 'Tel: 617-502-1700', 'Funder:', 'Gilead Sciences, Inc.', 'Sponsor-', 'Investigator:', 'Amy Colson, MD MPH', 'Principal Investigator', 'Community Research Initiative of New England', '529 Main Street', 'Boston, MA 02129', 'Tel: 617-502-1700', 'Email: acolson@crine.org', 'Sub-', 'Investigators:', 'Zev Schuman-Olivier, MD', 'Outpatient Addiction Services', 'Cambridge Health Alliance', '26 Central Street', 'Somerville, MA 02143', 'Tel: 617-665-1000', 'Email: zschuman@challiance.org', 'Hannah B. Olivet, MD', 'Senior Clinical Investigator', '529 Main Street', 'Boston, MA 02129', 'Tel: 617-502-1700', 'Email: holivet@crine.org', 'Medical', 'Monitor:', 'Jonathan S. Appelbaum, MD, FACP, AAHIVS', 'Laurie L. Dozier, Jr., MD, Education Director and Professor of Internal Medicine', 'Chair, Department of Clinical Sciences', 'Florida State University College of Medicine', '1115 West Call Street, Suite 3140-F', 'Tallahassee, FL 32306-4300', 'Tel: (617)502-1799', 'jonathan.appelbaum@med.fsu.edu', '1']['Table of Contents', '1', 'PROTOCOL SYNOPSIS', '5', '2', 'GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS', '10', '3', 'INTRODUCTION', '13', '3.1', 'BACKGROUND AND RATIONALE', '13', '3.2', 'EPCLUSA', '14', '3.3', 'BUPRENORPHINE/NALOXONE', '16', '3.4', 'COMPLIANCE', '17', '4', 'OBJECTIVES.', '17', '4.1', 'PRIMARY OBJECTIVE:', '17', '4.2', 'SECONDARY OBJECTIVES:', '18', '4.3', 'EXPLORATORY OBJECTIVE:', '18', '5', 'STUDY DESIGN', '18', '5.1', 'TREATMENT PLAN AND REGIMEN', '18', '5.2', 'SUBJECT RECRUITMENT', '18', '5.3', 'VISIT SCHEDULE', '18', '5.4', 'HCV VIROLOGIC RESPONSE-BASED TREATMENT STOPPING CRITERIA', '19', '5.5', 'TREATMENT DISCONTINUATION CRITERIA', '19', '6', 'SUBJECT POPULATION', '19', '6.1', 'NUMBER OF SUBJECTS AND SUBJECT SELECTION', '19', '6.2', 'INCLUSION CRITERIA FOR CLINICAL SUBJECTS', '19', '6.3', 'EXCLUSION CRITERIA FOR CLINICAL SUBJECTS', '20', '6.4', 'ELIGIBILITY CRITERIA FOR PROVIDER PARTICIPANTS', '21', '7', 'MEDICINAL PRODUCT', '21', '7.1', 'ENROLLMENT AND TREATMENT', '21', '7.2', 'DESCRIPTION AND HANDLING OF EPCLUSA', '21', '7.2.1', 'Formulation', '21', '7.2.2', 'Packaging and Labeling', '22', '7.2.3', 'Storage and Handling', '22', '7.2.4', 'Dosage and Administration of Epclusa', '22', '7.3', 'PRIOR AND CONCOMITANT MEDICATIONS', '22', '7.4', 'MONITORING ACCOUNTABILITY AND STUDY DRUG ADHERENCE FOR EPCLUSA', '23', '8', 'STUDY PROCEDURES', '24', '8.1', 'INFORMED CONSENT', '24', '8.2', 'SCREENING VISIT (DAY - -28 TO DAY 0)', '25', '8.3', 'TREATMENT ASSESSMENTS', '26', '8.3.1', 'Baseline/Day 1 Visit', '26', '8.3.2', 'Weeks 2, 4, 6, 8, 10 (+/-3 days)', '26', '8.3.3', 'End of Treatment (+/-3 days)', '26', '8.3.4', 'Early Termination Visit', '26', '8.4', 'POST-TREATMENT ASSESSMENTS', '27', '8.4.1', 'Post-Treatment Week 4 and 12 (+/- 5 days)', '27', '8.5', 'UNSCHEDULED VISIT', '27', 'CRI 15-05 Protocol 13SEP2017', 'Page 2']\n\n###\n\n", "completion": "END"}